The Aspen Group’s Asia-Pacific presence has been extended to include an office in Selangor, Malaysia.
This business unit, which was established in June 2012, will begin trading on 1 July 2013. The initial product range will include Zyloric, Oroxine, Trandate, Lanoxin, Imuran, Alkeran, Leukeran, Myleran and Lanvis with ongoing focus and extension taking place to meet the needs of the Malaysian citizens.
Aspen Malaysia will market and sell a basket of cardiovascular, endocrine and metabolic, immunosuppressant and oncology therapeutic products.